NCT00317915已完成3 期
The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 主要终点
- Development of overt nephropathy
研究概览
简要总结
The aim of this multicenter, doubleblind, randomized study was to investigate the renoprotective effect of irbesartan treatment in patients with type 2 diabetes and microalbuminuria (a precursor of diabetic kidney disease). 590 patients were randomized to a median 24 months of treatment with 300 mg irbesartan once daily, 150 mg irbesartan once daily or placebo. Time to development of overt nephropathy, defined by persistent proteinuria, was the primary outcome measure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes. Hypertension. Persistent microalbuminuria. Serum creatinine concentration of no more than 1.5 mg per deciliter (133 µmol per liter) for men and no more than 1.1 mg per deciliter (97 µmol per liter) for women. -
排除标准
- •Nondiabetic kidney disease. Cancer. Life-threatening disease with death expected to occur within two years. Indication for angiotensin-converting- enzyme (ACE) inhibitors or angiotensin-II-receptor antagonists. -
结局指标
主要结局
Development of overt nephropathy
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt NephropathyDiabetes Mellitus, Type 2NCT00464776Novartis26
已完成
不适用
A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)HypertensionNCT01390415Organon and Co136
已完成
3 期
Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With MicroalbuminuriaHypertensionNCT00561964Sanofi241
已完成
4 期
Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes MellitusPROTEINURIAType 2 DiabetesHypertensionNCT00241085Novartis392
已完成
3 期
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension PatientsEssential HypertensionNCT05476354Handok Inc.271